News

The company has raised gross proceeds of C$5 million through the issuance of 100 million units. Each unit consists of one common share and one-half of one share

The Pharos Vitesse is Micrus Endovascular’s balloon-expandable stent for intracranial ischemic stenosis and wide-neck aneurysm treatment. Micrus intends to immediately begin selling the Pharos Vitesse stent in the

Mr Potts said: “While pleased with much of the progress that has been made by Biosign, it is with deep regret but with great hope for the future

Mr Ruggiero will report to Michael Kaminski, president and COO of Stereotaxis. He was most recently chief sales and marketing officer at DJ Orthopedics. Mr Ruggiero earned his

Under the agreement, Chiltern will provide services to EPS International from its network of offices in 23 countries throughout Europe, North America, South America and India. Similarly, EPS

BioAlliance Pharma’s muco-adhesive Loramyc (miconazole Lauriad) is already approved in Europe and completed a Phase III clinical trial in the US in immunocompromised patients. BioAlliance’s partnership with NovaMed

The Phase II study was a randomized, double-blind, and placebo-controlled dose-ranging study to evaluate the efficacy and safety of ABT-894 in approximately 200 adults with attention-deficit hyperactivity disorder

Under the agreement, Tikcro will provide BioCancell with $2.5 million in funding at the closing. Of this amount, $2 million will be allocated to a four-year convertible note

Johnson & Johnson’s McNeil Consumer Healthcare unit manufactures the branded treatment, which is also called Cetirizine hydrochloride syrup. Zyrtec syrup is a colorless to slightly yellow syrup containing